1.43 USD
-0.02 (-1.38%)
1.08 USD
-0.35 (-24.48%)
Overall TCON gets a fundamental rating of 4 out of 10. We evaluated TCON against 525 industry peers in the Biotechnology industry. While TCON seems to be doing ok healthwise, there are quite some concerns on its profitability. TCON is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year TCON was profitable.
- In the past year TCON had a positive cash flow from operations.
- TCON had negative earnings in each of the past 5 years.
- TCON had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- TCON's Return On Assets of 18.69% is amongst the best of the industry. TCON outperforms 99.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.69% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-97.7%
ROA(5y)-92.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 14.39%, TCON belongs to the top of the industry, outperforming 97.04% of the companies in the same industry.
- TCON does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 14.39% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- TCON does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for TCON has been increased compared to 1 year ago.
- There is no outstanding debt for TCON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- Based on the Altman-Z score of -36.21, we must say that TCON is in the distress zone and has some risk of bankruptcy.
- TCON's Altman-Z score of -36.21 is on the low side compared to the rest of the industry. TCON is outperformed by 93.03% of its industry peers.
- There is no outstanding debt for TCON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 0 | ||
| Altman-Z | -36.21 |
ROIC/WACCN/A
WACC74.74%
2.3 Liquidity
- A Current Ratio of 0.80 indicates that TCON may have some problems paying its short term obligations.
- TCON's Current ratio of 0.80 is on the low side compared to the rest of the industry. TCON is outperformed by 90.59% of its industry peers.
- TCON has a Quick Ratio of 0.80. This is a bad value and indicates that TCON is not financially healthy enough and could expect problems in meeting its short term obligations.
- TCON has a worse Quick ratio (0.80) than 90.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
- TCON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 808.59%, which is quite impressive.
- TCON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.05% yearly.
EPS 1Y (TTM)808.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-269.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y32.05%
Sales Q2Q%N/A
3.2 Future
- The Earnings Per Share is expected to decrease by -15.22% on average over the next years. This is quite bad
- The Revenue is expected to grow by 63.68% on average over the next years. This is a very strong growth
EPS Next Y-142.4%
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%
EPS Next 5Y-15.22%
Revenue Next Year-100%
Revenue Next 2Y-66.67%
Revenue Next 3Y32.08%
Revenue Next 5Y63.68%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 0.16, which indicates a rather cheap valuation of TCON.
- Compared to the rest of the industry, the Price/Earnings ratio of TCON indicates a rather cheap valuation: TCON is cheaper than 100.00% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.32, TCON is valued rather cheaply.
- TCON is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.16 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- 100.00% of the companies in the same industry are more expensive than TCON, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 0.62 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- TCON's earnings are expected to decrease with -84.04% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%
5. Dividend
5.1 Amount
- No dividends for TCON!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.43
-0.02 (-1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2024-05-14/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners9.71%
Inst Owner Change0%
Ins Owners214.98%
Ins Owner Change0%
Market Cap3.83M
Revenue(TTM)12.14M
Net Income(TTM)1.75M
Analysts80
Price Target31.11 (2075.52%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)51.34%
Min EPS beat(2)-9.57%
Max EPS beat(2)112.26%
EPS beat(4)3
Avg EPS beat(4)238.94%
Min EPS beat(4)-9.57%
Max EPS beat(4)537.41%
EPS beat(8)4
Avg EPS beat(8)115.22%
EPS beat(12)4
Avg EPS beat(12)66.7%
EPS beat(16)7
Avg EPS beat(16)54.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)771.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2457.58%
EPS NY rev (1m)0%
EPS NY rev (3m)-943.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.16 | ||
| Fwd PE | N/A | ||
| P/S | 0.32 | ||
| P/FCF | 0.62 | ||
| P/OCF | 0.62 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)9.07
EY634.27%
EPS(NY)-2.92
Fwd EYN/A
FCF(TTM)2.29
FCFY160.11%
OCF(TTM)2.29
OCFY160.11%
SpS4.53
BVpS-0.66
TBVpS-0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.69% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 14.39% | ||
| GM | N/A | ||
| FCFM | 50.52% |
ROA(3y)-97.7%
ROA(5y)-92.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover1.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 351.03% | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | -36.21 |
F-Score8
WACC74.74%
ROIC/WACCN/A
Cap/Depr(3y)149.7%
Cap/Depr(5y)98.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)808.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-269.44%
EPS Next Y-142.4%
EPS Next 2Y-51.36%
EPS Next 3Y-84.04%
EPS Next 5Y-15.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y32.05%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-66.67%
Revenue Next 3Y32.08%
Revenue Next 5Y63.68%
EBIT growth 1Y89.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y125.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.09%
OCF growth 3YN/A
OCF growth 5YN/A
TRACON PHARMACEUTICALS INC / TCON FAQ
Can you provide the ChartMill fundamental rating for TRACON PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 4 / 10 to TCON.
What is the valuation status for TCON stock?
ChartMill assigns a valuation rating of 4 / 10 to TRACON PHARMACEUTICALS INC (TCON). This can be considered as Fairly Valued.
How profitable is TRACON PHARMACEUTICALS INC (TCON) stock?
TRACON PHARMACEUTICALS INC (TCON) has a profitability rating of 2 / 10.
Can you provide the financial health for TCON stock?
The financial health rating of TRACON PHARMACEUTICALS INC (TCON) is 4 / 10.
What is the earnings growth outlook for TRACON PHARMACEUTICALS INC?
The Earnings per Share (EPS) of TRACON PHARMACEUTICALS INC (TCON) is expected to decline by -142.4% in the next year.